Skip to main content

Genetic Predisposition

0
Pipeline Programs
4
Companies
2
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

4 companies ranked by most advanced pipeline stage

Human BioSciences
Human BioSciencesWV - Martinsburg
1 program
Digital Care PlansN/A1 trial
Active Trials
NCT05736497Completed164Est. Jun 2025
Genome & Company
Genome & CompanyKorea - Suwon
1 program
Digital Care PlansN/A
Eureka Therapeutics
Eureka TherapeuticsCA - Emeryville
1 program
tDCSN/A
Innovation Pharmaceuticals
1 program
tDCSN/A1 trial
Active Trials
NCT06402266Completed13Est. Nov 2023

Trial Timeline

Clinical trial activity over time

2022
2023
2024
2025
2026
Human BioSciencesDigital Care Plans
Innovation PharmaceuticalstDCS

Clinical Trials (2)

Total enrollment: 177 patients across 2 trials

Care Plans for Cancer Predisposition

Start: Aug 2023Est. completion: Jun 2025164 patients
N/ACompleted

Simultaneous tDCS and Computerised Gamified Short-term Memory Task Feasibility

Start: Jul 2022Est. completion: Nov 202313 patients
N/ACompleted

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

4 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.